Genomic characterization of response to chemoradiation in urothelial bladder cancer

Neil B. Desai, Sasinya N. Scott, Emily C. Zabor, Eugene K. Cha, Joseph Hreiki, John P. Sfakianos, Ricardo Ramirez, Aditya Bagrodia, Jonathan E. Rosenberg, Dean F. Bajorin, Michael F. Berger, Bernard H. Bochner, Michael J. Zelefsky, Marisa A. Kollmeier, Irina Ostrovnaya, Hikmat A. Al-Ahmadie, David B. Solit, Gopa Iyer

Research output: Contribution to journalArticle

21 Scopus citations

Abstract

BACKGROUND: The authors characterized the genetic landscape of chemoradiation-treated urothelial carcinoma of the bladder (UCB) with the objective of identifying potential correlates of response. METHODS: Primary tumors with (n = 8) or without (n = 40) matched recurrent tumors from 48 patients who had non-metastatic, high-grade UCB and received treatment primarily with chemoradiation were analyzed using a next-generation sequencing assay enriched for cancer-related and canonical DNA damage response (DDR) genes. Protein expression of meiotic recombination 11 homolog (MRE11), a previously suggested biomarker, was assessed in 44 patients. Recurrent tumors were compared with primary tumors, and the clinical impact of likely deleterious DDR gene alterations was evaluated. RESULTS: The profile of alterations approximated that of prior UCB cohorts. Within 5 pairs of matched primary-recurrent tumors, a median of 92% of somatic mutations were shared. A median 33% of mutations were shared between 3 matched bladder-metastasis pairs. Of 26 patients (54%) who had DDR gene alterations, 12 (25%) harbored likely deleterious alterations. In multivariable analysis, these patients displayed a trend toward reduced bladder recurrence (hazard ratio, 0.32; P =.070) or any recurrence (hazard ratio, 0.37; P =.070). The most common of these alterations, ERCC2 (excision repair cross-complementation group 2) mutations, were associated with significantly lower 2-year metastatic recurrence (0% vs 43%; log-rank P =.044). No impact of MRE11 protein expression on outcome was detected. CONCLUSIONS: A similar mutation profile between primary and recurrent tumors suggests that pre-existing, resistant clonal populations represent the primary mechanism of chemoradiation treatment failure. Deleterious DDR genetic alterations, particularly recurrent alterations in ERCC2, may be associated with improved chemoradiation outcomes in patients with UCB. A small sample size necessitates independent validation of these observations. Cancer 2016;122:3715-23.

Original languageEnglish (US)
Pages (from-to)3715-3723
Number of pages9
JournalCancer
Volume122
Issue number23
DOIs
StatePublished - Dec 1 2016

Keywords

  • DNA damage response
  • bladder chemoradiation
  • bladder preservation
  • excision repair cross-complementation group 2 (ERCC2)
  • radiation resistance

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Genomic characterization of response to chemoradiation in urothelial bladder cancer'. Together they form a unique fingerprint.

  • Cite this

    Desai, N. B., Scott, S. N., Zabor, E. C., Cha, E. K., Hreiki, J., Sfakianos, J. P., Ramirez, R., Bagrodia, A., Rosenberg, J. E., Bajorin, D. F., Berger, M. F., Bochner, B. H., Zelefsky, M. J., Kollmeier, M. A., Ostrovnaya, I., Al-Ahmadie, H. A., Solit, D. B., & Iyer, G. (2016). Genomic characterization of response to chemoradiation in urothelial bladder cancer. Cancer, 122(23), 3715-3723. https://doi.org/10.1002/cncr.30219